{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:16:59Z","timestamp":1780499819234,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04830-3","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:04:50Z","timestamp":1776099890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report"],"prefix":"10.1186","volume":"27","author":[{"given":"Rushuang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"3","key":"4830_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1053\/j.semdp.2020.01.001","volume":"37","author":"Q Cai","year":"2020","unstructured":"Cai Q, Hendricks AR. Membranous nephropathy: a ten-year journey of discoveries. Semin Diagn Pathol. 2020;37(3):116\u201320.","journal-title":"Semin Diagn Pathol"},{"issue":"10","key":"4830_CR2","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","volume":"18","author":"SJ Barbour","year":"2023","unstructured":"Barbour SJ, Fervenza FC, Induruwage D, et al. Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy. Clin J Am Soc Nephrol. 2023;18(10):1283\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4830_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.12659\/MSM.896090","volume":"22","author":"X Li","year":"2016","unstructured":"Li X, Wei D, Zhou Z, et al. Anti-PLA2R antibodies in Chinese patients with membranous nephropathy. Med Sci Monit. 2016;22:1630\u20136.","journal-title":"Med Sci Monit"},{"key":"4830_CR4","doi-asserted-by":"publisher","first-page":"663680","DOI":"10.3389\/fmed.2021.663680","volume":"8","author":"S Gao","year":"2021","unstructured":"Gao S, Cui Z, Wang X, et al. Rituximab therapy for primary membranous nephropathy in a Chinese cohort. Front Med. 2021;8:663680.","journal-title":"Front Med"},{"issue":"15","key":"4830_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2217\/imt-2021-0044","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen M, Le W, et al. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy. Immunotherapy. 2022;14(15):1237\u201344.","journal-title":"Immunotherapy"},{"issue":"10","key":"4830_CR6","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1681\/ASN.2014070640","volume":"26","author":"P Ruggenenti","year":"2015","unstructured":"Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 2015;26(10):2545\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4830_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"1","key":"4830_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"4830_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000356050","volume":"3","author":"S Marinaki","year":"2013","unstructured":"Marinaki S, Skalioti C, Boletis JN. B cell depletion: rituximab in glomerular disease and transplantation. Nephron Extra. 2013;3(1):125\u201330.","journal-title":"Nephron Extra"},{"issue":"24","key":"4830_CR10","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/jcm10245847","volume":"10","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L, Allinovi M, Rocco P, et al. Rituximab therapy for adults with nephrotic syndromes: standard schedules or B cell-targeted therapy? J Clin Med. 2021;10(24):5847.","journal-title":"J Clin Med"},{"issue":"6","key":"4830_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2215\/CJN.0000000694","volume":"20","author":"SJ Barbour","year":"2025","unstructured":"Barbour SJ, Ronco P, Praga M, et al. Predicting remission in antiphospholipase A2 receptor antibody-associated membranous nephropathy: a secondary analysis of the GEMRITUX, MENTOR, and STARMEN trials. Clin J Am Soc Nephrol. 2025;20(6):854\u201365.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4830_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","volume":"28","author":"K Dahan","year":"2017","unstructured":"Dahan K, Debiec H, Plaisier E, et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. 2017;28(1):348\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"4830_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck","year":"2011","unstructured":"Beck LH, Fervenza FC, Beck DM, et al. Rituximab-Induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4830_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11255-020-02633-5","volume":"53","author":"L Huang","year":"2021","unstructured":"Huang L, Dong QR, Zhao YJ, et al. Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis. Int Urol Nephrol. 2021;53(1):111\u20139.","journal-title":"Int Urol Nephrol"},{"key":"4830_CR15","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","volume":"12","author":"M Teisseyre","year":"2021","unstructured":"Teisseyre M, Cremoni M, Boyer-Suavet S, et al. Rituximab immunomonitoring predicts remission in membranous nephropathy. Front Immunol. 2021;12:738788.","journal-title":"Front Immunol"},{"key":"4830_CR16","doi-asserted-by":"publisher","first-page":"593288","DOI":"10.3389\/fimmu.2021.593288","volume":"12","author":"V Tesar","year":"2021","unstructured":"Tesar V, Hruskova Z. Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy. Front Immunol. 2021;12:593288.","journal-title":"Front Immunol"},{"issue":"2","key":"4830_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cei.12729","volume":"183","author":"RA Sinico","year":"2016","unstructured":"Sinico RA, Mezzina N, Trezzi B, et al. Immunology of membranous nephropathy: from animal models to humans. Clin Exp Immunol. 2016;183(2):157\u201365.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"4830_CR18","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpneph1007","volume":"5","author":"P Ruggenenti","year":"2009","unstructured":"Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: less might be enough. Nat Clin Pract Nephrol. 2009;5(2):76\u20137.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"1","key":"4830_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/0886022X.2022.2033265","volume":"44","author":"G Stefan","year":"2022","unstructured":"Stefan G, Stancu S, Zugravu A, et al. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. Ren Fail. 2022;44(1):258\u201368.","journal-title":"Ren Fail"},{"issue":"12","key":"4830_CR20","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/ckj\/sfab116","volume":"14","author":"E Jatem-Escalante","year":"2021","unstructured":"Jatem-Escalante E, Mart\u00edn-Conde ML, Gr\u00e0cia-Lavedan E, et al. Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy. Clin Kidney J. 2021;14(12):2556\u201362.","journal-title":"Clin Kidney J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04830-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:21:22Z","timestamp":1780496482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04830-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4830"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04830-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8533075\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article updated to correct the affiliation numbering and corresponding author email id.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any potentially identifiable images or data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}